Welcome to our dedicated page for Zymeworks news (Ticker: ZYME), a resource for investors and traders seeking the latest updates and insights on Zymeworks stock.
Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. The company's mission is to make a meaningful difference for people impacted by difficult-to-treat cancers and other serious diseases.
Zymeworks specializes in developing best-in-class bi-specific antibodies and antibody-drug conjugates (ADCs) to treat oncology, autoimmunity, and inflammatory diseases. Their proprietary platforms, including Azymetric™, Albucore™, and ZymeLink™, enable the creation of highly potent bi-specific antibodies and multivalent protein therapeutics targeting a range of indications.
The company's leading therapeutic candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently in multiple Phase 1, Phase 2, and pivotal clinical trials globally. Zanidatamab is being developed as a targeted treatment for patients with HER2-expressing cancers. Recent milestones include the acceptance of a Biologics License Application (BLA) by the FDA and China's National Medical Products Administration (NMPA) for second-line treatment of HER2-positive biliary tract cancers (BTC).
Zymeworks is also advancing a deep preclinical pipeline, including candidates like zanidatamab zovodotin (ZW49) and new investigational drugs ZW171 and ZW191, with plans for multiple IND filings in 2024 and 2025. The company is financially robust, with a cash runway extending into the second half of 2027, bolstered by strategic partnerships with BeiGene and Jazz Pharmaceuticals, among others.
The company's complementary therapeutic platforms and fully integrated drug development engine enable precise engineering of differentiated product candidates, offering potential best-in-class treatments for various challenging diseases. For more information, visit www.zymeworks.com.
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company, announced eleven abstracts accepted for presentation at the American Association for Cancer Research Annual Meeting from April 14-19, 2023, in Orlando, FL. The abstracts will showcase advancements in the company’s antibody drug conjugates, multispecific antibodies, and clinical candidates, including ZW171 and ZW191. The management team will host a conference call on April 18, 2023, at 6:30 pm EST to discuss these developments. The abstracts reflect Zymeworks' commitment to pioneering treatments for difficult-to-treat cancers.
Zymeworks Inc. (ZYME) reported a significant turnaround in 2022, achieving $412.5 million in total revenue, a sharp increase from $26.7 million in 2021. The company posted a net income of $124.3 million ($1.90 per share) compared to a net loss of $211.8 million in the previous year. Cash resources stand at $492.2 million, ensuring a runway through 2026. Key developments include positive Phase 2 study results for zanidatamab and a substantial licensing agreement with Jazz Pharmaceuticals, potentially worth up to $1.76 billion. Zymeworks aims to advance multiple clinical studies and develop five novel product candidates over the next five years.
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company, announced its participation in two upcoming investor conferences. The management will attend the Barclays Global Healthcare Conference on March 14-15, presenting on March 14 at 10:45 am EST in Miami Beach, FL. Additionally, the team will join the Cantor: The Future of Oncology Virtual Symposium on April 3-4 for virtual meetings and a fireside chat. Presentations and webcasts will be accessible on Zymeworks’ website.
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company, will announce its fourth quarter and full year 2022 financial results on March 7, 2023, after market close. A conference call and webcast will follow at 4:30 p.m. EST to discuss the results and provide a corporate update. Interested parties can access the live webcast and replay on Zymeworks' website. The company focuses on developing multifunctional biotherapeutics for difficult-to-treat cancers, with its lead candidate zanidatamab currently in various clinical trials. Zymeworks aims to make impactful advancements in cancer treatment.
Zymeworks Inc. (Nasdaq: ZYME), a biotechnology firm focused on developing multifunctional biotherapeutics, recently announced its participation in two upcoming investor conferences. The first is the Guggenheim Oncology Conference on February 8-9, featuring one-on-one meetings and a fireside chat on February 9 at 2:10 pm ET in New York, NY. The second is the SVB Securities Global Biopharma Conference on February 14-15, with a presentation scheduled for February 14 at 10:40 am ET. All events will be accessible via Zymeworks’ website.
Jazz Pharmaceuticals and Zymeworks announced results from a Phase 2 trial for zanidatamab, a HER2-targeted bispecific antibody, showcasing compelling efficacy in advanced HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA) patients. The trial revealed an overall confirmed objective response rate (cORR) of 79% and a disease control rate (DCR) of 92%. Notably, the 18-month overall survival (OS) rate was 84%, with median progression-free survival (mPFS) of 12.5 months. The ongoing Phase 3 trial, HERIZON-GEA-01, is expected to provide further data that could support regulatory submissions.
Zymeworks Inc. (Nasdaq: ZYME) has announced key strategic updates and financial guidance for 2023. The company has successfully closed its collaboration with Jazz Pharmaceuticals, marking a significant financial transformation. As of December 31, 2022, Zymeworks reported approximately $490 million in cash resources, with expected cash burn for 2023 between $90 million and $120 million. The company plans to enhance its research and development efforts, with a focus on zanidatamab and zanidatamab zovodotin. Key priorities include advancing multiple clinical trials and establishing additional collaborations.
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company, will participate in the JP Morgan Healthcare Conference with one-on-one meetings and a corporate presentation on January 12 at 10:30 am PT. The event aims to showcase Zymeworks' innovative biotherapeutics for cancer treatment. The company is advancing candidates like zanidatamab and zanidatamab zovodotin, targeting HER2-expressing cancers. Presentations will be accessible on Zymeworks’ website.
Jazz Pharmaceuticals and Zymeworks announced that Jazz has exercised its option to continue exclusive rights for the development and commercialization of zanidatamab, following positive clinical data from the HERIZON-BTC-01 trial in biliary tract cancers. The trial showed a 41.3% objective response rate among patients with HER2-amplified disease. Jazz will pay Zymeworks $325 million and may owe up to $1.76 billion in future milestone payments. Zanidatamab aims to provide HER2-targeted therapy for challenging cancers, currently lacking approved treatments.
Zymeworks Inc. (NASDAQ: ZYME) announced positive topline results from its Phase 2b HERIZON-BTC-01 trial of zanidatamab in patients with HER2-amplified biliary tract cancers (BTC). The therapy achieved a confirmed objective response rate of 41.3% and a median duration of response of 12.9 months. Pending regulatory approvals, zanidatamab could become the first HER2-targeted treatment for BTC. The safety profile remained consistent with prior studies, with no new safety signals identified. Full trial results are expected in 2023.
FAQ
What is the current stock price of Zymeworks (ZYME)?
What is the market cap of Zymeworks (ZYME)?
What is Zymeworks Inc.?
What are the key therapeutic platforms of Zymeworks?
What is zanidatamab?
Which partnerships has Zymeworks formed for zanidatamab?
What recent regulatory milestones has Zymeworks achieved?
What financial outlook does Zymeworks have?
What are the current projects in Zymeworks' pipeline?
How does Zymeworks' pipeline address unmet medical needs?
What is the role of Zymeworks' platforms in drug development?
Where can I find more information about Zymeworks?
